摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,3,4-四氢-2-甲基-7-硝基异喹啉 | 14097-35-9

中文名称
1,2,3,4-四氢-2-甲基-7-硝基异喹啉
中文别名
——
英文名称
2-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline
英文别名
2-methyl-7-nitro-3,4-dihydro-1H-isoquinoline
1,2,3,4-四氢-2-甲基-7-硝基异喹啉化学式
CAS
14097-35-9
化学式
C10H12N2O2
mdl
——
分子量
192.217
InChiKey
PUMCPMLEPPOZRX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    57 °C
  • 沸点:
    296.9±40.0 °C(Predicted)
  • 密度:
    1?+-.0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    49.1
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:4911e4c1e5ebf22641484f32398f5422
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2017098421A1
    公开(公告)日:2017-06-15
    The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    本发明涉及取代苯并噻二嗪衍生物。具体而言,本发明涉及式(I)化合物:其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂,可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病,如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此,本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
  • 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors
    申请人:Uehling David Edward
    公开号:US20090149456A1
    公开(公告)日:2009-06-11
    The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
    本发明提供了2-嘧啶基吡唑并吡啶化合物,含有该化合物的组合物,以及它们的制备方法和作为药物的应用。
  • [EN] ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS<br/>[FR] ANILINOPYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE 1 PROGÉNITRICES HÉMATOPOÏÉTIQUES (HPK1)
    申请人:ARIAD PHARMA INC
    公开号:WO2018102366A1
    公开(公告)日:2018-06-07
    The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.
    这项发明涉及用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的HPK1抑制剂,其化学式为:其中A、R1、R2、R3、R4、R5、R6、R16、R17、X1、X2、X3、X4、m和n如本文所述。
  • [EN] IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION<br/>[FR] IMIDAZOPYRIDINES UTILISÉES COMME NOUVEL ÉCHAFAUDAGE POUR L'INHIBITION DES KINASES À CIBLES MULTIPLES
    申请人:ABBOTT LAB
    公开号:WO2011053476A1
    公开(公告)日:2011-05-05
    Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).
    抑制蛋白激酶的化合物,含有这些化合物的组合物以及使用这些化合物治疗疾病的方法被披露。公式(I)。
  • [EN] PYRIMIDINE INHIBITORS OF KINASE ACTIVITY<br/>[FR] INHIBITEURS PYRIMIDINES DE L'ACTIVITÉ KINASE
    申请人:ABBOTT LAB
    公开号:WO2010138576A1
    公开(公告)日:2010-12-02
    The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.
    本发明涉及式(I)的化合物或其药用可接受的盐或溶剂,其中G1、R2、R3、R4、R5、n、p、q、Ar1和Ar2在描述中有定义。本发明还涉及制备所述化合物的方法,以及包含所述化合物的组合物,用于抑制IGF-IR等激酶。
查看更多